Insider Buying: Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Director Buys 100,000 Shares of Stock

Key Points

• Aurinia Pharmaceuticals Director Kevin Tang purchased 100,000 shares at $11.34 each, valuing the transaction at $1,134,000, increasing his total ownership in the company.
• The stock price of Aurinia Pharmaceuticals rose 2.2%, reaching $11.70, with significant trading volume reported at over 3 million shares.
• Aurinia Pharmaceuticals recently reported earnings of $0.16 EPS, missing estimates by $0.01, while revenue exceeded expectations at $70.01 million.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Get Free Report) TSE: AUP Director Kevin Tang acquired 100,000 shares of the company's stock in a transaction that occurred on Monday, August 4th. The shares were acquired at an average price of $11.34 per share, with a total value of $1,134,000.00. Following the completion of the transaction, the director owned 11,129,500 shares in the company, valued at $126,208,530. The trade was a 0.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kevin Tang also recently made the following trade(s):

• On Tuesday, August 5th, Kevin Tang bought 200,000 shares of Aurinia Pharmaceuticals stock. The stock was purchased at an average cost of $11.68 per share, with a total value of $2,336,000.00.
• On Friday, August 1st, Kevin Tang bought 1,000,000 shares of Aurinia Pharmaceuticals stock. The stock was purchased at an average cost of $10.12 per share, with a total value of $10,120,000.00.

Aurinia Pharmaceuticals Trading Up 2.2%

Shares of AUPH stock traded up $0.25 on Tuesday, hitting $11.70. The company had a trading volume of 3,144,408 shares, compared to its average volume of 1,573,970. The firm has a market cap of $1.54 billion, a P/E ratio of 27.21 and a beta of 1.23. The stock's 50-day moving average is $8.49 and its two-hundred day moving average is $8.18. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. Aurinia Pharmaceuticals Inc has a twelve month low of $5.20 and a twelve month high of $11.80.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.17 by ($0.01). The company had revenue of $70.01 million during the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. On average, equities research analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AUPH. Hussman Strategic Advisors Inc. grew its stake in Aurinia Pharmaceuticals by 70.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 357,000 shares of the biotechnology company's stock worth $3,024,000 after purchasing an additional 147,000 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $925,000. Nordea Investment Management AB grew its stake in Aurinia Pharmaceuticals by 1.5% during the second quarter. Nordea Investment Management AB now owns 355,000 shares of the biotechnology company's stock worth $3,117,000 after purchasing an additional 5,400 shares during the period. Vanguard Personalized Indexing Management LLC acquired a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $92,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in Aurinia Pharmaceuticals during the second quarter worth approximately $238,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AUPH has been the subject of a number of recent research reports. Royal Bank Of Canada upped their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.